Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

BUY
$30.35 - $53.15 $4,916 - $8,610
162 Added 1.6%
10,257 $507,000
Q3 2022

Nov 14, 2022

SELL
$31.97 - $49.37 $232,166 - $358,524
-7,262 Reduced 41.84%
10,095 $328,000
Q2 2022

Aug 15, 2022

BUY
$35.61 - $76.23 $618,082 - $1.32 Million
17,357 New
17,357 $684,000
Q1 2022

May 16, 2022

SELL
$57.56 - $82.54 $179,069 - $256,781
-3,111 Closed
0 $0
Q4 2021

Feb 15, 2022

SELL
$72.5 - $100.68 $58,797 - $81,651
-811 Reduced 20.68%
3,111 $242,000
Q3 2021

Nov 15, 2021

BUY
$90.24 - $124.05 $57,934 - $79,640
642 Added 19.57%
3,922 $374,000
Q2 2021

Aug 16, 2021

SELL
$93.66 - $139.27 $115,014 - $171,023
-1,228 Reduced 27.24%
3,280 $408,000
Q1 2021

May 14, 2021

BUY
$116.57 - $155.01 $58,518 - $77,815
502 Added 12.53%
4,508 $594,000
Q4 2020

Feb 12, 2021

BUY
$99.61 - $142.12 $146,426 - $208,916
1,470 Added 57.97%
4,006 $531,000
Q3 2020

Nov 13, 2020

SELL
$72.92 - $102.01 $218,614 - $305,825
-2,998 Reduced 54.17%
2,536 $259,000
Q2 2020

Aug 13, 2020

BUY
$55.75 - $92.75 $308,520 - $513,278
5,534 New
5,534 $481,000
Q1 2020

May 15, 2020

SELL
$37.9 - $104.44 $390,445 - $1.08 Million
-10,302 Closed
0 $0
Q4 2019

Feb 14, 2020

SELL
$77.66 - $99.74 $44,499 - $57,151
-573 Reduced 5.27%
10,302 $953,000
Q3 2019

Nov 14, 2019

BUY
$90.37 - $122.49 $173,239 - $234,813
1,917 Added 21.4%
10,875 $983,000
Q2 2019

Aug 14, 2019

BUY
$89.51 - $118.04 $168,099 - $221,679
1,878 Added 26.53%
8,958 $1.06 Million
Q1 2019

May 20, 2019

BUY
$61.98 - $96.5 $6,012 - $9,360
97 Added 1.39%
7,080 $613,000
Q4 2018

Feb 13, 2019

BUY
$56.04 - $82.66 $391,327 - $577,214
6,983 New
6,983 $441,000

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $10.2B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Allstate Corp Portfolio

Follow Allstate Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allstate Corp, based on Form 13F filings with the SEC.

News

Stay updated on Allstate Corp with notifications on news.